Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2010

01-11-2010 | Clinical Study - Patient Study

Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas

Authors: Kuan-Yin Tseng, Min-Huey Chung, Huey-Kang Sytwu, Horng-Mo Lee, Kuan-Yu Chen, Chen Chang, Chih-Kung Lin, Che-Hung Yen, Jia-Hong Chen, Gu-Jiun Lin, Hsin-I Ma, Yi-Shian Yeh, Da-Tong Ju, Ming-Ying Liu, Dueng-Yuan Hueng

Published in: Journal of Neuro-Oncology | Issue 2/2010

Login to get access

Abstract

Prediction of recurrence remains a challenge in histopathological benign/grade I tumors. Osteopontin (OPN) plays important roles in tumorigenesis, invasion, and metastasis of several human cancers. In this study, we investigated OPN protein expression by evaluating the differences between recurrent and non-recurrent histologically benign meningiomas. Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II). Cytoplasmic OPN staining was evaluated by means of immunohistochemistry (IHC) score and by use of the Allred-8-unit system. We examined clinical biological data, their relationship with tumor recurrence, and the expression of OPN. Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001). An OPN Allred score between 0 and 3 was associated with a recurrence-free time of more than 25 months. In comparison, an OPN Allred score from 4 to 8 was indicative of a shorter average recurrence-free time. We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas. Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
Literature
1.
go back to reference Maiuri F, De Caro Mdel B, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E (2007) Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 82:63–68CrossRefPubMed Maiuri F, De Caro Mdel B, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, de Divitiis E (2007) Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol 82:63–68CrossRefPubMed
2.
go back to reference Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK (2007) MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 27:407–412CrossRefPubMed Vankalakunti M, Vasishta RK, Das Radotra B, Khosla VK (2007) MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Neuropathology 27:407–412CrossRefPubMed
3.
go back to reference Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6:819–830CrossRefPubMed Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC (2006) The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6:819–830CrossRefPubMed
4.
go back to reference Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30–31:92–102CrossRefPubMed Denhardt DT, Noda M (1998) Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 30–31:92–102CrossRefPubMed
5.
go back to reference Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85PubMed
6.
go back to reference Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632CrossRefPubMed Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632CrossRefPubMed
7.
go back to reference Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMed Tuck AB, Chambers AF (2001) The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 6:419–429CrossRefPubMed
8.
go back to reference Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475CrossRefPubMed Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475CrossRefPubMed
9.
go back to reference Toy H, Yavas O, Eren O, Genc M, Yavas C (2009) Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res 15:203–207CrossRefPubMed Toy H, Yavas O, Eren O, Genc M, Yavas C (2009) Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res 15:203–207CrossRefPubMed
10.
go back to reference Tunio GM, Hirota S, Nomura S, Kitamura Y (1998) Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 122:1087–1090PubMed Tunio GM, Hirota S, Nomura S, Kitamura Y (1998) Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch Pathol Lab Med 122:1087–1090PubMed
11.
go back to reference Ho DM, Hsu CY, Ting LT, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94:1538–1547CrossRefPubMed Ho DM, Hsu CY, Ting LT, Chiang H (2002) Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 94:1538–1547CrossRefPubMed
12.
go back to reference Takahashi JA, Ueba T, Hashimoto N, Nakashima Y, Katsuki N (2004) The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 61: 149–155; discussion 155–146 Takahashi JA, Ueba T, Hashimoto N, Nakashima Y, Katsuki N (2004) The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 61: 149–155; discussion 155–146
13.
go back to reference Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190CrossRefPubMed Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190CrossRefPubMed
14.
go back to reference Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127CrossRefPubMed Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127CrossRefPubMed
15.
go back to reference Jan HJ, Lee CC, Shih YL, Hueng DY, Ma HI, Lai JH, Wei HW, Lee HM (2010) Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 12:58–70 Jan HJ, Lee CC, Shih YL, Hueng DY, Ma HI, Lai JH, Wei HW, Lee HM (2010) Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 12:58–70
16.
go back to reference Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226CrossRefPubMed Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226CrossRefPubMed
17.
go back to reference Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135–146PubMed Shijubo N, Uede T, Kon S, Nagata M, Abe S (2000) Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 11:135–146PubMed
18.
go back to reference Mantle RE, Lach B, Delgado MR, Baeesa S, Belanger G (1999) Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg 91:375–383CrossRefPubMed Mantle RE, Lach B, Delgado MR, Baeesa S, Belanger G (1999) Predicting the probability of meningioma recurrence based on the quantity of peritumoral brain edema on computerized tomography scanning. J Neurosurg 91:375–383CrossRefPubMed
19.
go back to reference Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, Jung HW (2002) Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol 60:235–245CrossRefPubMed Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, Jung HW (2002) Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol 60:235–245CrossRefPubMed
20.
go back to reference Hsu DW, Efird JT, Hedley-Whyte ET (1998) MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441–452CrossRefPubMed Hsu DW, Efird JT, Hedley-Whyte ET (1998) MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441–452CrossRefPubMed
21.
go back to reference Karja V, Sandell PJ, Kauppinen T, Alafuzoff I (2010) Does protein expression predict recurrence of benign World Health Organization grade I meningioma? Hum Pathol 41:199–207CrossRefPubMed Karja V, Sandell PJ, Kauppinen T, Alafuzoff I (2010) Does protein expression predict recurrence of benign World Health Organization grade I meningioma? Hum Pathol 41:199–207CrossRefPubMed
22.
go back to reference Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120CrossRefPubMed Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27:114–120CrossRefPubMed
23.
go back to reference Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O (2009) Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol 94:383–388CrossRefPubMed Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O (2009) Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol 94:383–388CrossRefPubMed
Metadata
Title
Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas
Authors
Kuan-Yin Tseng
Min-Huey Chung
Huey-Kang Sytwu
Horng-Mo Lee
Kuan-Yu Chen
Chen Chang
Chih-Kung Lin
Che-Hung Yen
Jia-Hong Chen
Gu-Jiun Lin
Hsin-I Ma
Yi-Shian Yeh
Da-Tong Ju
Ming-Ying Liu
Dueng-Yuan Hueng
Publication date
01-11-2010
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0164-2

Other articles of this Issue 2/2010

Journal of Neuro-Oncology 2/2010 Go to the issue